Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135849851> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W3135849851 endingPage "251" @default.
- W3135849851 startingPage "251" @default.
- W3135849851 abstract "251 Background: Glutaminolysis plays a significant role in the metabolic reprogramming of cancer cell growth and proliferation. Glutaminase (GLS1), the rate-limiting enzyme of the glutamine pathway, is frequently dysregulated in cancer. High GLS1 expression is reported in colorectal and breast cancers and has been found to correlate with the tumor stage and disease progression. Furthermore, a new orally bioavailable glutaminase inhibitor (CB-839) is in early phase clinical trials in select tumors. The purpose of this study is to investigate the status of GLS1 expression in prostate cancer (PCa) and to correlate expression levels with clinicopathologic parameters. Methods: Radical prostatectomy samples from 154 patients with prostate adenocarcinoma were retrospectively reviewed and used to evaluate GLS1 expression by immunohistochemistry (IHC). The IHC expression score was calculated by multiplying the intensity of the stain by the proportion of cells staining; cases were then segmented into negative, low, or high expression groups. In addition, 41 samples of benign prostate tissue were used as a control. Associations between GLS1 levels and clinicopathologic parameters were analyzed by Pearson’s chi-squared and Log-rank tests. Results: GLS1 expression in the benign controls were negative, low, and high in 59%, 41%, 0% of cases, respectively, compared to 53%, 21.5%, 25.5%, respectively, in PCa (p < 0.003). Most PCa patients were age < 60 (55.8%), white (78.6%), stage T2 (52.9%), node negative (80.5%), Grade Group 3 (44%), and non-smokers (63.6%). There was no difference between GLS1 expression and age, race, Gleason score, stage, node status, and smoking status by univariate analysis. The median biochemical-progression free survival for negative, low, and high expression was 10, 9, and 10 years, respectively (p = 0.7). Conclusions: In our study, PCa samples were more likely to have GLS1 expression compared to benign controls. Although GLS1 expression did not appear to be a prognostic marker, our cohort was enriched for cases with localized disease and low-to-intermediate grade PCa. As a result, future studies are warranted to evaluate the expression levels in high grade and advanced PCa cases to determine a role for prognostic and or therapeutic implication to justify future preclinical studies with CB-839." @default.
- W3135849851 created "2021-03-15" @default.
- W3135849851 creator A5008470507 @default.
- W3135849851 creator A5009872882 @default.
- W3135849851 creator A5024247892 @default.
- W3135849851 creator A5036722177 @default.
- W3135849851 creator A5046352646 @default.
- W3135849851 creator A5049078993 @default.
- W3135849851 creator A5051696178 @default.
- W3135849851 creator A5062482259 @default.
- W3135849851 creator A5090879940 @default.
- W3135849851 date "2021-02-20" @default.
- W3135849851 modified "2023-10-16" @default.
- W3135849851 title "Immunohistochemical evaluation of glutaminase expression in prostate adenocarcinoma and correlation with clinicopathologic parameters." @default.
- W3135849851 doi "https://doi.org/10.1200/jco.2021.39.6_suppl.251" @default.
- W3135849851 hasPublicationYear "2021" @default.
- W3135849851 type Work @default.
- W3135849851 sameAs 3135849851 @default.
- W3135849851 citedByCount "0" @default.
- W3135849851 crossrefType "journal-article" @default.
- W3135849851 hasAuthorship W3135849851A5008470507 @default.
- W3135849851 hasAuthorship W3135849851A5009872882 @default.
- W3135849851 hasAuthorship W3135849851A5024247892 @default.
- W3135849851 hasAuthorship W3135849851A5036722177 @default.
- W3135849851 hasAuthorship W3135849851A5046352646 @default.
- W3135849851 hasAuthorship W3135849851A5049078993 @default.
- W3135849851 hasAuthorship W3135849851A5051696178 @default.
- W3135849851 hasAuthorship W3135849851A5062482259 @default.
- W3135849851 hasAuthorship W3135849851A5090879940 @default.
- W3135849851 hasConcept C109549099 @default.
- W3135849851 hasConcept C121608353 @default.
- W3135849851 hasConcept C126322002 @default.
- W3135849851 hasConcept C142724271 @default.
- W3135849851 hasConcept C143998085 @default.
- W3135849851 hasConcept C146357865 @default.
- W3135849851 hasConcept C151730666 @default.
- W3135849851 hasConcept C170493617 @default.
- W3135849851 hasConcept C204232928 @default.
- W3135849851 hasConcept C2776235491 @default.
- W3135849851 hasConcept C2777008409 @default.
- W3135849851 hasConcept C2779466945 @default.
- W3135849851 hasConcept C2780192828 @default.
- W3135849851 hasConcept C2781182431 @default.
- W3135849851 hasConcept C61174792 @default.
- W3135849851 hasConcept C71924100 @default.
- W3135849851 hasConcept C86803240 @default.
- W3135849851 hasConceptScore W3135849851C109549099 @default.
- W3135849851 hasConceptScore W3135849851C121608353 @default.
- W3135849851 hasConceptScore W3135849851C126322002 @default.
- W3135849851 hasConceptScore W3135849851C142724271 @default.
- W3135849851 hasConceptScore W3135849851C143998085 @default.
- W3135849851 hasConceptScore W3135849851C146357865 @default.
- W3135849851 hasConceptScore W3135849851C151730666 @default.
- W3135849851 hasConceptScore W3135849851C170493617 @default.
- W3135849851 hasConceptScore W3135849851C204232928 @default.
- W3135849851 hasConceptScore W3135849851C2776235491 @default.
- W3135849851 hasConceptScore W3135849851C2777008409 @default.
- W3135849851 hasConceptScore W3135849851C2779466945 @default.
- W3135849851 hasConceptScore W3135849851C2780192828 @default.
- W3135849851 hasConceptScore W3135849851C2781182431 @default.
- W3135849851 hasConceptScore W3135849851C61174792 @default.
- W3135849851 hasConceptScore W3135849851C71924100 @default.
- W3135849851 hasConceptScore W3135849851C86803240 @default.
- W3135849851 hasIssue "6_suppl" @default.
- W3135849851 hasLocation W31358498511 @default.
- W3135849851 hasOpenAccess W3135849851 @default.
- W3135849851 hasPrimaryLocation W31358498511 @default.
- W3135849851 hasRelatedWork W10753024 @default.
- W3135849851 hasRelatedWork W1093006 @default.
- W3135849851 hasRelatedWork W11104898 @default.
- W3135849851 hasRelatedWork W11607516 @default.
- W3135849851 hasRelatedWork W15269199 @default.
- W3135849851 hasRelatedWork W16043632 @default.
- W3135849851 hasRelatedWork W17081240 @default.
- W3135849851 hasRelatedWork W20905478 @default.
- W3135849851 hasRelatedWork W7518501 @default.
- W3135849851 hasRelatedWork W9959812 @default.
- W3135849851 hasVolume "39" @default.
- W3135849851 isParatext "false" @default.
- W3135849851 isRetracted "false" @default.
- W3135849851 magId "3135849851" @default.
- W3135849851 workType "article" @default.